HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The disposition of recainam hydrochloride during and after intravenous loading and maintenance infusion in cardiac patients.

Abstract
Recainam hydrochloride is a newly synthesized propylurea compound demonstrating potent antidysrhythmic effects. Recainam was administered as a loading dose of 3 mg/kg/40 minutes followed by a continuous infusion of 0.9 mg/kg/hr for 23 hours and 20 minutes to ten patients with cardiac disease and frequent PVCs (more than 30/hr). A total of 15 plasma samples were drawn over 36 hours during and after the infusion. Plasma recainam concentration was determined by high performance liquid chromatography (HPLC). The mean (+/- SD) postload and 24-hour plasma concentrations were 5.19 +/- 0.51 and 3.41 +/- 0.71 micrograms/mL, respectively. The data were best described by a two-compartment model yielding the following mean (+/- SD) pharmacokinetic parameters: lambda 1 = 2.62 +/- 0.68 hr-1, lambda 2 = 0.144 +/- 0.014 hr-1, t1/2 lambda 2 = 4.84 +/- 0.46 hr, CLT = 0.268 +/- 0.057 L/hr/kg, CLR = 0.143 +/- 0.052 L/kg/hr, CLNR = 0.125 +/- 0.041 L/hr/kg, Vdss = 1.3 +/- 0.19 L/kg, and Vd lambda 2 = 1.9 +/- 0.43 L/kg. There were no adverse reactions. Based on these data, recainam can be safely administered as a loading dose followed by a continuous infusion in patients with stable cardiac disease without significant ventricular dysfunction.
AuthorsE M Hampton, M I Anastasiou-Nana, J N Nanas, J M Nappi, D M Capuzzi, J L Anderson
JournalJournal of clinical pharmacology (J Clin Pharmacol) Vol. 27 Issue 12 Pg. 951-6 (Dec 1987) ISSN: 0091-2700 [Print] England
PMID3437067 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Anti-Arrhythmia Agents
  • Phenylurea Compounds
  • recainam
  • Creatinine
Topics
  • Adult
  • Aged
  • Anti-Arrhythmia Agents (administration & dosage, pharmacokinetics, therapeutic use)
  • Cardiovascular Diseases (drug therapy)
  • Creatinine (blood)
  • Drug Evaluation
  • Female
  • Half-Life
  • Humans
  • Infusions, Intravenous
  • Male
  • Middle Aged
  • Phenylurea Compounds (administration & dosage, pharmacokinetics, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: